Tackling Influenza with Broadly Neutralizing Antibodies

Overview

Journal Curr Opin Virol

Publisher Elsevier

Specialty Microbiology

Date 2017 May 22

PMID 28527859

Citations 81

Authors

Davide Corti

Elisabetta Cameroni

Barbara Guarino

Nicole L Kallewaard

Qing Zhu

Antonio Lanzavecchia

Affiliations

Soon will be listed here.

Abstract

Monoclonal antibodies have revolutionized the treatment of several human diseases, including cancer, autoimmunity and inflammatory conditions and represent a new frontier for the treatment of infectious diseases. In the last decade, new methods have allowed the efficient interrogation of the human antibody repertoire from influenza immune individuals and the isolation of several monoclonal antibodies capable of dealing with the high variability of influenza viruses. Here, we will provide a comprehensive overview of the specificity, antiviral and immunological mechanisms of action and development into the clinic of broadly reactive monoclonal antibodies against influenza A and B viruses.

Citing Articles

Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches.

Bonomini A, Mercorelli B, Loregian A Cell Mol Life Sci. 2025; 82(1):75.

PMID: 39945883 PMC: 11825441. DOI: 10.1007/s00018-025-05611-1.

Pair combinations of human monoclonal antibodies fully protected mice against bunyavirus SFTSV lethal challenge.

Li B, Qin X, Qu J, Wu G, Zhang W, Jiang Z PLoS Pathog. 2025; 21(1):e1012889.

PMID: 39888973 PMC: 11785279. DOI: 10.1371/journal.ppat.1012889.

Phenomenological Modeling of Antibody Response from Vaccine Strain Composition.

Ovchinnikov V, Karplus M Antibodies (Basel). 2025; 14(1.

PMID: 39846614 PMC: 11755667. DOI: 10.3390/antib14010006.

Human antibody polyreactivity is governed primarily by the heavy-chain complementarity-determining regions.

Chen H, Zhang Y, Huang J, Sawant M, Smith M, Rajagopal N Cell Rep. 2024; 43(10):114801.

PMID: 39392756 PMC: 11564698. DOI: 10.1016/j.celrep.2024.114801.

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.

Casazza J, Hofstetter A, Costner P, Holman L, Hendel C, Widge A NPJ Vaccines. 2024; 9(1):171.

PMID: 39289377 PMC: 11408684. DOI: 10.1038/s41541-024-00959-0.

References

Rajao D, Chen H, Perez D, Sandbulte M, Gauger P, Loving C . Vaccine-associated enhanced respiratory disease is influenced by haemagglutinin and neuraminidase in whole inactivated influenza virus vaccines. J Gen Virol. 2016; 97(7):1489-1499. DOI: 10.1099/jgv.0.000468. View

Yewdell J . To dream the impossible dream: universal influenza vaccination. Curr Opin Virol. 2013; 3(3):316-21. PMC: 3713083. DOI: 10.1016/j.coviro.2013.05.008. View

Ekiert D, Bhabha G, Elsliger M, Friesen R, Jongeneelen M, Throsby M . Antibody recognition of a highly conserved influenza virus epitope. Science. 2009; 324(5924):246-51. PMC: 2758658. DOI: 10.1126/science.1171491. View

Wrammert J, Koutsonanos D, Li G, Edupuganti S, Sui J, Morrissey M . Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011; 208(1):181-93. PMC: 3023136. DOI: 10.1084/jem.20101352. View

Tharakaraman K, Subramanian V, Viswanathan K, Sloan S, Yen H, Barnard D . A broadly neutralizing human monoclonal antibody is effective against H7N9. Proc Natl Acad Sci U S A. 2015; 112(35):10890-5. PMC: 4568252. DOI: 10.1073/pnas.1502374112. View

Ramos E, Mitcham J, Koller T, Bonavia A, Usner D, Balaratnam G . Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. J Infect Dis. 2014; 211(7):1038-44. DOI: 10.1093/infdis/jiu539. View

Grandea 3rd A, Olsen O, Cox T, Renshaw M, Hammond P, Chan-Hui P . Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A. 2010; 107(28):12658-63. PMC: 2906546. DOI: 10.1073/pnas.0911806107. View

Webster R, Govorkova E . H5N1 influenza--continuing evolution and spread. N Engl J Med. 2006; 355(21):2174-7. DOI: 10.1056/NEJMp068205. View

Terajima M, Cruz J, Co M, Lee J, Kaur K, Wrammert J . Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies. J Virol. 2011; 85(24):13463-7. PMC: 3233150. DOI: 10.1128/JVI.05193-11. View

10.

Wu Y, Cho M, Shore D, Song M, Choi J, Jiang T . A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus. Nat Commun. 2015; 6:7708. PMC: 4518248. DOI: 10.1038/ncomms8708. View

11.

Monsalvo A, Batalle J, Lopez M, Krause J, Klemenc J, Hernandez J . Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med. 2010; 17(2):195-9. PMC: 3034774. DOI: 10.1038/nm.2262. View

12.

Schnell J, Chou J . Structure and mechanism of the M2 proton channel of influenza A virus. Nature. 2008; 451(7178):591-5. PMC: 3108054. DOI: 10.1038/nature06531. View

13.

Nabel G, Wei C, Ledgerwood J . Vaccinate for the next H2N2 pandemic now. Nature. 2011; 471(7337):157-8. DOI: 10.1038/471157a. View

14.

Mozdzanowska K, Feng J, Eid M, Zharikova D, Gerhard W . Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. Virology. 2006; 352(2):418-26. DOI: 10.1016/j.virol.2006.05.008. View

15.

Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W . Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013; 368(20):1888-97. DOI: 10.1056/NEJMoa1304459. View

16.

Goldstein E, Viboud C, Charu V, Lipsitch M . Improving the estimation of influenza-related mortality over a seasonal baseline. Epidemiology. 2012; 23(6):829-38. PMC: 3516362. DOI: 10.1097/EDE.0b013e31826c2dda. View

17.

Lee P, Yoshida R, Ekiert D, Sakai N, Suzuki Y, Takada A . Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc Natl Acad Sci U S A. 2012; 109(42):17040-5. PMC: 3479480. DOI: 10.1073/pnas.1212371109. View

18.

Peiris M, Yuen K, Leung C, Chan K, Ip P, Lai R . Human infection with influenza H9N2. Lancet. 1999; 354(9182):916-7. DOI: 10.1016/s0140-6736(99)03311-5. View

19.

Hung I, To K, Lee C, Lee K, Chan K, Yan W . Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011; 52(4):447-56. PMC: 7531589. DOI: 10.1093/cid/ciq106. View

20.

Tan G, Krammer F, Eggink D, Kongchanagul A, Moran T, Palese P . A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol. 2012; 86(11):6179-88. PMC: 3372189. DOI: 10.1128/JVI.00469-12. View